DaVita HealthCare Partners Inc. reported income for the second quarter of 2015 of $170 million, or $0.78 per share, after adjusting for $29 million in debt redemption charges and an $8 million tax adjustment related to the company’s settlement of a whistleblower suit, which beat analysts’ expectations.
The suit alleged that, for years, DaVita intentionally created waste when administering Zemplar and Venofer, and submitted claims for such waste for reimbursement, in violation of the False Claims Act.
DaVita’s dialysis treatments
Total U.S. dialysis treatments for the second quarter of 2015 were 6,463,058, or 82,860 treatments per day, representing a per day increase of 4.3% over the second quarter of 2014. Non-acquired treatment growth and normalized non-acquired treatment growth in the second quarter of 2015 were both 3.7% over the second quarter of 2014.
As of June 30, 2015, DaVita provided dialysis services to approximately 184,000 patients at 2,306 outpatient dialysis centers, of which 2,210 centers are located in the United States and 96 centers are located in ten countries outside of the United States. During the second quarter of 2015, DaVita opened 13 new dialysis centers in the United States. The company also acquired one and opened two new dialysis centers outside of the United States.
DaVita is updating the low end of its consolidated operating income for 2015 to now be in the range of $1.825 billion to $1.925 billion, compared to earlier numbers of $1.800 billion to $1.925 billion.
DaVita is also updating the low end of our operating income for Kidney Care for 2015 to now be in the range of $1.600 billion to $1.650 billion, compared to earlier numbers of $1.575 billion to $1.650 billion.